{"id":629,"date":"2018-04-16T20:17:45","date_gmt":"2018-04-16T19:17:45","guid":{"rendered":"https:\/\/10storks.com\/?p=629"},"modified":"2018-04-16T20:17:45","modified_gmt":"2018-04-16T19:17:45","slug":"stemcyte","status":"publish","type":"post","link":"https:\/\/imedicalsociety.org\/stemcyte\/","title":{"rendered":"StemCyte"},"content":{"rendered":"
StemCyte is one of the leading umbilical cord blood banking systems present on the international level, with locations in the USA, India and Taiwan.\u00a0 SyemCyte represents a combination of a public cord blood banking<\/a> facility and a private umbilical cord blood bank<\/a>.<\/p>\n To compare StemCyte with other cord blood banks<\/a>, see our cord blood banking reviews article<\/a>. To discover which are the preferred features for a cord blood banking institution, go to this article<\/a>. In general, this company does not stand so well when compared with thers such as ViaCord,<\/a> Americord,<\/a> or CBR,<\/a> to name a few.<\/p>\n The milestone of this institution, StemCyte, is to provide a diverse and global umbilical cord blood pool from which both public<\/a> and private<\/a> users would have therapeutic benefit.\u00a0 StemCyte has reached the highest diversity of umbilical cord blood units and has provided umbilical cord blood to a significant number of patients worldwide.\u00a0 Approximately two thousand donated umbilical cord blood units<\/a> were released for therapeutic use from the public bank directly to the hospitals around the world.\u00a0 A successful merging of private and public cord blood banking allows StemCyte to provide the highest standards in the field of umbilical cord blood collection, storage and release for therapeutic use.<\/p>\n The diversity and an impressive number of umbilical cord blood units stored in the facility give StemCyte the ability to cooperate with leading global experts, and some public cord blood banks<\/a>, and create an Advanced Therapeutics initiative, which resulted in clinical trials investigating the role of cord blood<\/a> in the treatment of thalassemia, spinal cord injury, and stroke.\u00a0 No other company possesses in our cord blood banking reviews<\/a> such business model, consisted of three major components: private<\/a> and public blood banking<\/a> with substantial potential for investigating new modalities of umbilical cord blood use.<\/p>\n <\/p>\n